Brief: Aprea Therapeutics Announces Acquisition Of Atrin Pharmaceuticals And Reports Q1 Results
16/05/2022 14:30
May 16 (Reuters) - Aprea Therapeutics Inc APRE.O :
* APREA THERAPEUTICS ANNOUNCES ACQUISITION OF ATRIN
PHARMACEUTICALS INC. AND REPORTS FIRST QUARTER 2022 FINANCIAL
RESULTS
* Q1 LOSS PER SHARE $0.36
* APREA - BELIEVES CASH, CASH EQUIVALENTS AS OF MARCH 31,
2022
WILL BE SUFFICIENT TO MEET ITS CURRENT PROJECTED OPERATING
REQUIREMENTS THROUGH H2 2023
* AS OF MARCH 31, 2022, COMPANY HAD $47.6 MILLION OF CASH
AND CASH
EQUIVALENTS
* NET LOSS WAS $0.36 PER SHARE FOR QUARTER ENDED MARCH 31,
2022
Source text for Eikon: ID:nGNX5n8kQ4
Further company coverage: APRE.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Aprea Therapeutics
See all newsAprea Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Aprea Therapeutics Q2 net loss widens on higher R&D costs
Aprea Therapeutics Inc expected to post a loss of 23 cents a share - Earnings Preview
Brief: Aprea Therapeutics Provides Acesot-1051 Program Update For Wee1 Inhibitor Apr-1051 Accelerating And Expanding Enrollment. Clinical Data Presentation Planned For Q4 2026
Brief: Aprea Therapeutics - Files For Resale Of Up To 5.5 Million Shares By Selling Stockholders - SEC Filing